At a glance
- Originator Banyu; Merck & Co
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 01 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 01 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)